PARP1 and endometrial cancer: It has been previously shown that PTEN loss-of-function is associated with higher sensitivity to PARP inhibitors through a synthetic lethal mechanism in prostate, lung, cerebral, [24–28] and, notably, endometrial cancer [29, 30].